Duyuru • Mar 07
Evolva Holding SA, Annual General Meeting, Apr 12, 2024 Evolva Holding SA, Annual General Meeting, Apr 12, 2024. Duyuru • Feb 02
Evolva Holding SA ADR - Sponsored to Be Deleted from OTC Equity Evolva Holding SA American Depositary Receipts - Sponsored will be deleted from OTC Equity effective February 02, 2024, due to ADR /GDR Program Terminated. Duyuru • Dec 29
Evolva Holding to Seek the Delisting of Its Shares from SIX Swiss Exchange Lallemand has completed the acquisition of Swiss biotechnology firm Evolva AG from the holding entity Evolva Holding (SWX:EVE), according to a statement published on December 28, 2023. The deal was wrapped up on December 28, 2023 after shareholders of Evolva Holding AG granted approval on December 21, 2023. Evolva Holding SA will now seek the delisting of its shares from SIX Swiss Exchange. Duyuru • Nov 23
Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million. Danstar Ferment AG enters into an agreement to acquire Evolva AG form Evolva Holding SA (SWX:EVE) for CHF 30 million on November 21, 2023. The purchase price is set at CHF 20 million, subject to customary post-signing/completion adjustments and in addition, Evolva Holding SA and Danstar Ferment AG have entered into an earn-out agreement providing for additional future contingent purchase price payments of up to CHF 10 million, depending on the achievement of certain product-based sales targets over the next 18 months. Evolva's Board of Directors unanimously supports the transaction and recommends approval of the transaction to its shareholders. Evolva will invite shareholders to an extraordinary shareholders’ meeting (EGM) in the coming days. The EGM is expected to be held still this year to ask shareholders to approve the transaction and Evolva’s liquidation and to resolve on the delisting of Evolva from SIX Swiss Exchange. The net proceeds from the transaction will be distributed to the shareholders of Evolva Holding SA after satisfaction of all creditor claims and the warranty periods of the SPA have lapsed. New Risk • Nov 22
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CHF6.01m (US$6.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Market cap is less than US$10m (CHF6.01m market cap, or US$6.80m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (CHF10m net loss in 2 years). New Risk • Nov 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 22% per year over the past 5 years. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CHF21.8m market cap, or US$24.2m). New Risk • Sep 28
New major risk - Revenue and earnings growth Earnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF14.1m market cap, or US$15.4m). New Risk • Sep 13
New major risk - Revenue and earnings growth Earnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CHF12m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (CHF11.0m market cap, or US$12.4m). Duyuru • Sep 07
Evolva Receives Approval for Veri-Te Resveratrol in Thailand Evolva has received approval for its Veri-te Resveratrol from the THAI Food and Drug Administration for use as an ingredient in dietary supplements. This approval is further testimony to Evolva's market expansion activities. Thailand will be the fifth country in South-East Asia after the Philippines, Malaysia, Vietnam and Taiwan where Veri-te Resveratrol is available for use in foods and dietary supplements. The approval was obtained with support of Breko and Brenntag Ingredients (Thailand) Public Company Limited. long-term partner Breko is a supplier of products for the food and beverage industry as well as for food supplements, functional food and cosmetic products. Breko and Brenntag ingredients (Thailand) Public Company Limited have been working together in Thailand for many years, bringing innovative ingredients from Europe to the region. The launch, in the format of a technical seminar, is scheduled at Vitafoods ASIA which will take place from 20 - 22 September 2023 in Bangkok, Thailand. This is an important tradeshow for the nutraceutical and food and beverage industry in the region. Duyuru • Jul 25
Evolva Receives FDA Approval for Veri-teTM Resveratrol in Taiwan Evolva has received approval for its Veri-teTM Resveratrol from the Taiwanese Food and Drug Administration (TFDA) for use as an ingredient in foods and dietary supplements. The approval is an important milestone as it opens up Taiwan as a further South-East Asian market after the Philippines, Malaysia and Vietnam where Veri-teTM Resveratrol is already available for use in foods and dietary supplements. The approval was obtained in close partnership with Champion Co. Ltd., Evolva's Taiwanese distribution partner, who supported Evolva throughout the registration process. Champion Co. Ltd. will also accompany market introduction. The launch is scheduled for 28th of July in the format of a technical seminar during Bio Asia Taiwan inTaipei, a key tradeshow in the region. Reported Earnings • Mar 10
Full year 2022 earnings released: CHF0.04 loss per share (vs CHF0.047 loss in FY 2021) Full year 2022 results: CHF0.04 loss per share. Revenue: CHF15.5m (up 57% from FY 2021). Net loss: CHF43.4m (loss widened 5.1% from FY 2021). Revenue is forecast to grow 43% p.a. on average during the next 2 years, compared to a 6.6% growth forecast for the Chemicals industry in Switzerland. Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Aug 27
First half 2022 earnings released: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021) First half 2022 results: CHF0.03 loss per share (vs CHF0.03 loss in 1H 2021). Revenue: CHF8.13m (up 28% from 1H 2021). Net loss: CHF28.9m (loss widened 14% from 1H 2021). Over the next year, revenue is forecast to grow 67%, compared to a 12% growth forecast for the Chemicals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 20% per year and the company’s share price has also fallen by 20% per year. Duyuru • Aug 26
Evolva Holding SA Provides Revenue Guidance for the Full Year 2022 and 2025 Evolva Holding SA provided revenue guidance for the full year 2022 and 2025. Revenue growth of 50% at constant currencies to CHF 15 million in 2022 expected, with positive double-digit gross contribution margin. The company aims to achieve an annual revenue growth of 40% to 60% in the coming years and targets to reach a revenue level of CHF 45 million to CHF 50 million in 2025. Duyuru • May 25
Evolva Holding SA announced that it has received CHF 6.3226 million in funding Evolva Holding SA announced a private placement of 62,600,000 common shares at a price of CHF 0.101 per share for gross proceeds of CHF 6,322,600 on May 24, 2022. The transaction included participation from long-term oriented institutional investors, selected members of the Board of Directors and management for CHF 1,000,000. Duyuru • May 08
Evolva Holding SA Announces Management Appointments Evolva Holding SA at its annual general meeting held on May 5, 2022, approved elected Andreas Pfluger, a senior leader with broad international experience especially in consumer goods industries, as well as Andreas Weigelt, Board representative of shareholder Veraison, as new members of the Board of Directors. Shareholders further elected Andreas Pfluger as member of the Compensation Committee. Price Target Changed • Apr 27
Price target decreased to CHF0.21 Down from CHF0.26, the current price target is an average from 3 analysts. New target price is 100% above last closing price of CHF0.11. Stock is down 45% over the past year. The company is forecast to post a net loss per share of CHF0.02 next year compared to a net loss per share of CHF0.047 last year. Board Change • Apr 27
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Scientific Advisory Board Jörg Bohlmann is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Breakeven Date Change • Mar 15
Forecast to breakeven in 2023 The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule. Breakeven Date Change • Mar 15
Forecast to breakeven in 2023 The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 63% is required to achieve expected profit on schedule. Price Target Changed • Mar 14
Price target decreased to CHF0.23 Down from CHF0.27, the current price target is an average from 3 analysts. New target price is 90% above last closing price of CHF0.12. Stock is down 41% over the past year. The company is forecast to post a net loss per share of CHF0.013 next year compared to a net loss per share of CHF0.047 last year. Reported Earnings • Mar 12
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: CHF0.05 loss per share (down from CHF0.038 loss in FY 2020). Revenue: CHF9.88m (up 31% from FY 2020). Net loss: CHF41.3m (loss widened 38% from FY 2020). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 140%, compared to a 11% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 22% per year. Duyuru • Feb 08
Evolva Holding SA Announces Executive Changes Evolva announced that the Board of Directors has appointed Christian Wichert as new CEO. Christian Wichert has a proven track record of transforming organizations and managing for performance. His broad international experience in Europe as well as North and South America spans across the Specialty Chemicals/Life Sciences, Water and Consumer Packaged Goods industries, among others. As a results-oriened leader he builds high performing teams focused on business delivery. Christian Wichert will take over responsibility of Chief Executive Officer as of February 8. He will present himself to the media and the investment community on occasion of the publication of Evolva's full-year 2021 results on March 10, 2022. Oliver Walker, who played a pivotal role in the company's strategic development and transformation over the last five years, will hand over responsibilities as of February 8, 2022. He will be available to support the company in an advisory role over the next 12 months. Breakeven Date Change • Jan 21
Forecast to breakeven in 2023 The 3 analysts covering Evolva Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 35% per year to 2022. The company is expected to make a profit of CHF3.28m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Duyuru • Dec 28
Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA Evolva Holding SA announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 12 million on December 27, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2023. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion. Reported Earnings • Aug 29
First half 2021 earnings released: CHF0.03 loss per share (vs CHF0.02 loss in 1H 2020) The company reported a mediocre first half result with increased losses and weaker control over costs, although revenues improved. First half 2021 results: Revenue: CHF6.38m (up 61% from 1H 2020). Net loss: CHF25.4m (loss widened 88% from 1H 2020). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Duyuru • May 17
Evolva Holding SA announced that it expects to receive CHF 20 million in funding from Nice & Green SA Evolva Holding SA (SWX:EVE) announced that it has entered into an agreement with returning investor Nice & Green SA for a private placement of convertible securities for gross proceeds of CHF 20 million on May 17, 2021. The transaction will be completed in multiple tranches. The transaction is expected to close by the end of 2022. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume during the six trading days preceding the conversion. Executive Departure • Mar 10
Chief Financial Officer has left the company On the 2nd of March, Andre Pennartz's tenure as Chief Financial Officer ended after 1.1 years in the role. We don't have any record of a personal shareholding under Andre's name. A total of 3 executives have left over the last 12 months. Price Target Changed • Mar 03
Price target raised to CHF0.32 Up from CHF0.29, the current price target is an average from 2 analysts. The new target price is 43% above the current share price of CHF0.22. As of last close, the stock is down 2.6% over the past year. Analyst Estimate Surprise Post Earnings • Mar 03
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 28%. Earnings per share (EPS) exceeded analyst estimates by 38%. Over the next year, revenue is forecast to grow 59%, compared to a 7.6% growth forecast for the Chemicals industry in Switzerland. Duyuru • Mar 03
Evolva Announces Management Changes Evolva announced that André Pennartz, CFO of Evolva, is leaving the company for personal reasons with immediate effect. Oliver Walker will take on the role of CFO ad interim until a successor is appointed. Reported Earnings • Mar 02
Full year 2020 earnings released: CHF0.038 loss per share (vs CHF0.028 loss in FY 2019) Full year 2020 results: Net loss: CHF29.9m (loss widened 38% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Duyuru • Jan 21
Evolva Launches L-Arabinose, a Natural Sugar Blocker and Reducing Sugar Evolva launched L-arabinose (previously known as EVE-X157/Z4), a natural sugar blocker used in food and beverages and reducing sugar applied in food processing. As people around the world continue to strive to live a healthier lifestyle, they are committed to helping their customers create healthier, more sustainable solutions. Studies show that L-arabinose as sugar blocker can support healthy blood sugar levels and weight management. It also has potential application as a prebiotic. As reducing sugar, L-arabinose is also frequently applied in the production of savoury flavors such as chicken and beef. Made by fermentation, Evolva's L-arabinose is fully renewable and sustainable, it has a high-purity level (>99%) and no hydrochloric acid is used in the manufacturing process. L-Arabinose is FEMA GRAS approved for use in food and beverages. L-Arabinose taste profile is well-suited for use in products such as yogurt, chocolate, soft drinks, ice cream, cereal, power bars and confectionary. With a wide range of applications, L-arabinose has a current market value of CHF 250 million, which is expected to grow by at least 5% per annum. Evolva is having commercial discussions with major customers, which include first supply volumes for 2021. Is New 90 Day High Low • Jan 20
New 90-day high: CHF0.24 The company is up 11% from its price of CHF0.22 on 22 October 2020. The Swiss market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period. Duyuru • Nov 06
Evolva Holding Sa Appoints Gerhard Lobmaier as Chief Operations Officer, Effective January 1, 2021 Evolva Holding SA announced that Effective January 1, 2021, Gerhard Lobmaier is appointed Evolva's Chief Operations Officer. In his role, he will lead the manufacturing and supply chain functions, supporting the optimization of the CMO network for Evolva, thus increasing security of supply and realizing cost savings. Prior to this appointment, he served in several global functions at Cognis and BASF. Is New 90 Day High Low • Oct 14
New 90-day low: CHF0.23 The company is down 17% from its price of CHF0.27 on 16 July 2020. The Swiss market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share. Duyuru • Oct 14
Processa Pharmaceuticals, Inc. Appoints Michael Floyd as Chief Operating Officer Processa Pharmaceuticals Inc. announced the appointment of Michael Floyd as the Company's Chief Operating Officer. Floyd is a serial entrepreneur who, over the last 15 years, has formed and been a senior executive in several life science organizations focused on the development of products to treat infectious and rare diseases, as well as the development of oncology drugs. He founded the early stage enterprise Neurologic, that in-licensed technology from the NIH for a diagnostic test for Alzheimer's disease. In 2006 he served as the CEO for the North American subsidiary of Arpida Ltd. and organized the phase 3 program for the NDA submission of an MRSA drug. Then after joining Gentium, SpA in 2011, he led the US efforts to remediate the NDA for defibrotide. More recently, Mr. Floyd co-founded Elion Oncology which licensed PCS6422 to Processa. Duyuru • Aug 26
Evolva Holding SA to Report Fiscal Year 2020 Results on Feb 25, 2021 Evolva Holding SA announced that they will report fiscal year 2020 results at 5:01 AM, GMT Standard Time on Feb 25, 2021 Duyuru • Jun 30
Evolva Holding SA announced that it expects to receive CHF 12 million in funding from Nice & Green SA Evolva Holding SA (SWX:EVE) announced that it has entered into an agreement with Nice & Green SA for a private placement of convertible securities for gross proceeds of up to CHF 12 million on June 29, 2020. The transaction will be completed in multiple tranches. The securities issued in the transaction will be redeemable either by converting them into ordinary shares or into cash. The conversion price will be set at 95% of the average price recorded during the lowest daily volume on SIX during the six trading days preceding the conversion. 
